EUCTR2007-004435-30-HU进行中（未招募）1 期
A RANDOMISED, 4-WEEK, PLACEBO-CONTROLLED, DOUBLE-BLIND, 6 ARM PARALLEL GROUP, DOSE-FINDING CLINICAL TRIAL, TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THREE DIFFERENT DOSES OF FORMOTEROL (6, 12 & 18µg) COMBINED WITH THE INHALED ANTICHOLINERGIC ACLIDINIUM BROMIDE 200µg, ACLIDINIUM BROMIDE 200µg MONOTHERAPY AND FORMOTEROL 12µg MONOTHERAPY ALL ADMINISTERED ONCE DAILY BY INHALATION VIA ALMIRALL INHALER IN PATIENTS WITH STABLE MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
aboratorios Almirall, S.A0 个研究点目标入组 513 人开始时间: 2008年1月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 513
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult male or non-pregnant, non-lactating female aged between 40 and 80 years old, both inclusive. Women of childbearing potential are allowed to enter the trial ONLY if they use TWO medically approved contraceptive measures (i.e., mechanical and pharmacological).
- •(A female is considered to be of childbearing potential unless she has had a hysterectomy, is at least one year post-menopause or has undergone tubal ligation. All women of childbearing potential must have a negative serum pregnancy test at the Screening Visit).
- •2. Patient with a clinical diagnosis of stable moderate to severe COPD (stages II and III) according to the GOLD 2006 classification (http://www.goldcopd.com).
- •3. Current, or ex-cigarette smoker with a smoking history of at least 10 pack-years.
- •Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and multiplying this figure by the number of years a person has smoked. For example, a person who smokes 40 cigarettes a day and has smoked for 10 years would have a 20 pack-year smoking history (40 cigarettes per day¸ 20 cigarettes per pack = 2; 2 x 10 years of smoking = 20 pack-year history).
- •Patients smoking other tobacco types will not be allowed, unless they meet the cigarette criterion as well.
- •4. Patient whose FEV1 at the Screening Visit measured between 30-45 minutes post inhalation of 400 mg of salbutamol is 30% = FEV1 <80% of the predicted normal value (i.e., 100 x Post-salbutamol FEV1/ Predicted FEV1 <80% and = 30%).
- •(Predicted normal values to be used for calculation purposes are to be based on European Community for Steel and Coal predicted values (Quanjer et al. 1993)).
- •5. Patient whose FEV1/FVC at the Screening Visit measured between 30-45 minutes post inhalation of 400 mg of salbutamol is <70% (i.e., 100 x Post-salbutamol FEV1/FVC <70%).
- •6. Patient whose COPD symptoms and FEV1 values at the time of randomisation are stable compared to the Screening Visit, according to the investigator’s medical judgment.
- •7. Patient who is eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients allowed to enter the trial must not present any of the following conditions at Screening Visit and/or before randomisation:
- •1. History or current diagnosis of asthma, allergic rhinitis or atopy, or exercise-induced bronchospasm.
- •2. Eosinophil count = 600 cells/mm3.
- •3. Clinically significant respiratory conditions at the time of Screening Visit defined as:
- •·Use of long-term oxygen therapy > 15h/day,
- •·Known active tuberculosis,
- •·History of interstitial lung or pulmonary thromboembolic disease,
- •·Pulmonary resection during the past 12 months,
- •·History of life-threatening COPD,
- •·History of bronchiectasis secondary to respiratory diseases others than COPD (e.g., cystic fibrosis, Kartagener’s syndrome, etc),
- •·Patients who in the investigator’s opinion may need to stop or start pulmonary rehabilitation or undergo a thoracotomy during the trial.
- •4. Hospitalisation due to COPD exacerbation, up to the 3 months prior to the Screening Visit.
- •5. Signs of a COPD exacerbation or respiratory infection (including the upper respiratory tract), up to the 6 weeks prior to the Screening Visit.
- •6. Clinically significant cardiovascular conditions at the time of Screening Visit defined as:
- •·Myocardial infarction within the previous 6 months,
- •·Unstable arrhythmia which has required changes in the pharmacological therapy or other intervention within the previous 12 months, or newly diagnosed arrhythmia within the previous 3 months.
- •·Hospitalisation within the previous 12 months for heart failure functional classes III (marked limitation of activity and only comfortable at rest) and IV (need of complete rest, confinement to bed or chair, discomfort at any physical activity and presence of symptoms at rest) as per the New York Heart Association classification (www.americanheart.org)
- •·Thoracic surgery within the previous 24 months
- •7. Presence of symptomatic prostatic hypertrophy and/or bladder neck obstruction. (However, patients with a diagnosis of these conditions but without symptoms due to stable concomitant medication for its treatment are allowed to enter trial).
- •8. Presence of narrow-angle glaucoma.
- •9. History of untoward reactions or known hypersensitivity to inhaled anticholinergics (including aclidinium bromide), ß2 adrenergic agonists or inhaled medication or any component thereof (including report of paradoxical bronchospasm).
- •10. Life expectancy of less than 1 year.
- •11. Prolonged QTcB interval (> 470 msec) in any of the ECGs performed before randomisation, and/or the use of drugs which may induce its prolongation.
- •12. Clinically relevant abnormalities in laboratory results, ECG parameters (other than QTcB), or physical examination if the abnormality defines a disease state listed as an exclusion criterion, except for those related to COPD.
- •13. Clinically significant diseases other than COPD, which, in the opinion of the investigator, may put the patient at risk because of the participation in the trial; or diseases which may influence the results of the study or the patient’s ability to take part in it.
- •14. Patient who does not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers will be excluded).
- •15. Patient who intends to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.
- •16. Patient who is unable or unlikely to be cooperative with the study requirements of taking the medication,
研究者
相似试验
已完成
不适用
A 4-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF L-000904218 IN PATIENTS WITH KNEE OR HIP OSTEOARTHRITIS-M169 Coxarthrosis, unspecified-M179 Gonarthrosis, unspecifiedCoxarthrosis, unspecifiedGonarthrosis, unspecifiedM169M179PER-072-05MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
1 期
A Clinical Trial on the Safety and Efficacy of 12 weeks of Varenicline (CHANTIX/CHAMPIX) for Smoking Cessation in Smokers with DepressioSmoking cessationMedDRA version: 13.1Level: PTClassification code 10053325Term: Smoking cessation therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-014916-37-DEPfizer Inc, 235 East 42nd Street, New York, NY 10017 US500
进行中（未招募）
不适用
A PHASE 4 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE (CP-526,555) 1MG BID FOR SMOKING CESSATION IN SUBJECTS WITH DEPRESSIOSmoking cessationMedDRA version: 12.1Level: LLTClassification code 10053325Term: Smoking cessation therapyEUCTR2009-014916-37-HUPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
不适用
A 14-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA - NDTreatment of fibromyalgiaMedDRA version: 6.1Level: PTClassification code 10048439MedDRA version: 9.1Level: LLTClassification code 10048439Term: FibromyalgiaEUCTR2006-000425-57-ITPFIZER740
进行中（未招募）
1 期
A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIAMedDRA version: 8.1Level: LLTClassification code 10048439FibromyalgiaEUCTR2006-000425-57-DKPfizer Inc./ Ann Arbor740